NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

NOVO.B.DK

283.7

+4.34%↑

GMAB.DK

1,581.5

+3.88%↑

COLO.B.DK

383.8

+1.29%↑

ZEAL.DK

332

+10.96%↑

AMBUB.DK

66.35

+3.67%↑

Search

H Lundbeck A-S

Затворен

44.56 1.41

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

44.54

Максимум

44.88

Ключови измерители

By Trading Economics

Приходи

1.7B

1.7B

Продажби

1.2B

7B

P/E

Средно за сектора

11.535

49.888

EPS

1.671

Дивидентна доходност

2.65

Марж на печалбата

23.601

Служители

5,000

EBITDA

598M

2.4B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.65%

2.38%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

833M

43B

Предишно отваряне

43.15

Предишно затваряне

44.56

H Lundbeck A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2026 г., 19:20 ч. UTC

Значими двигатели на пазара

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7.06.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7.06.2026 г., 18:00 ч. UTC

Печалби

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6.06.2026 г., 12:40 ч. UTC

Придобивния, сливания и поглъщания

Correction to Texas Billionaires Article America's Resort -- WSJ

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.06.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2026 г., 00:14 ч. UTC

Придобивния, сливания и поглъщания

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5.06.2026 г., 21:27 ч. UTC

Печалби

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5.06.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Hog Futures Tumble to Close Week -- Market Talk

5.06.2026 г., 19:10 ч. UTC

Пазарно говорене

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5.06.2026 г., 19:03 ч. UTC

Пазарно говорене

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5.06.2026 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5.06.2026 г., 18:47 ч. UTC

Пазарно говорене

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5.06.2026 г., 18:34 ч. UTC

Пазарно говорене

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5.06.2026 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5.06.2026 г., 17:50 ч. UTC

Печалби

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5.06.2026 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5.06.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

H Lundbeck A-S Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat